New drug aims to tame severe allergies by lowering key antibody
NCT ID NCT07408869
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called cizutamig in about 20 adults with IgE-mediated allergies, including food allergies. The main goal is to see if the drug can safely lower IgE levels, which are antibodies that trigger allergic reactions. Researchers will also monitor side effects and how the drug moves through the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diet tame chronic hives in teens?
- Can a new pill silence the itch of chronic hives?
- Ancient herbal blend put to the test against hay fever
- Can mapping fish allergy profiles in kids improve diagnosis?
- Can a pinpoint pollen dose unmask allergy triggers?
- Can an antihistamine–steroid combo pill beat standard allergy meds?